Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Research analysts at B. Riley issued their Q2 2025 earnings estimates for shares of Tango Therapeutics in a report issued on Monday, June 9th. B. Riley analyst Y. Zhi anticipates that the company will post earnings per share of ($0.35) for the quarter. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics' Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.33) EPS.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $5.39 million during the quarter, compared to analysts' expectations of $6.73 million.
Separately, HC Wainwright restated a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics presently has an average rating of "Buy" and an average price target of $12.20.
View Our Latest Stock Analysis on Tango Therapeutics
Tango Therapeutics Stock Up 1.5%
NASDAQ TNGX traded up $0.07 during trading on Wednesday, hitting $4.81. The stock had a trading volume of 1,105,372 shares, compared to its average volume of 1,572,038. The company has a market capitalization of $521.38 million, a PE ratio of -4.08 and a beta of 1.24. The firm has a 50 day moving average price of $1.88 and a 200 day moving average price of $2.40. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02.
Hedge Funds Weigh In On Tango Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in TNGX. Dynamic Technology Lab Private Ltd acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $33,000. Stonebrook Private Inc. acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Tango Therapeutics during the 4th quarter worth $35,000. Sherbrooke Park Advisers LLC purchased a new position in Tango Therapeutics in the fourth quarter valued at $38,000. Finally, Squarepoint Ops LLC purchased a new stake in Tango Therapeutics during the 4th quarter worth about $40,000. Hedge funds and other institutional investors own 78.99% of the company's stock.
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Featured Articles
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
